UA63876C2 - Method for treating schizophrenia and schizophreniform disorders - Google Patents

Method for treating schizophrenia and schizophreniform disorders Download PDF

Info

Publication number
UA63876C2
UA63876C2 UA96020584A UA96020584A UA63876C2 UA 63876 C2 UA63876 C2 UA 63876C2 UA 96020584 A UA96020584 A UA 96020584A UA 96020584 A UA96020584 A UA 96020584A UA 63876 C2 UA63876 C2 UA 63876C2
Authority
UA
Ukraine
Prior art keywords
thiadiazol
tetrahydro
methylpyridine
methyl
pyridine
Prior art date
Application number
UA96020584A
Other languages
English (en)
Ukrainian (uk)
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of UA63876C2 publication Critical patent/UA63876C2/uk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
UA96020584A 1993-08-19 1994-08-15 Method for treating schizophrenia and schizophreniform disorders UA63876C2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10930093A 1993-08-19 1993-08-19
PCT/DK1994/000305 WO1995005174A1 (en) 1993-08-19 1994-08-15 Antipsychotic method

Publications (1)

Publication Number Publication Date
UA63876C2 true UA63876C2 (en) 2004-02-16

Family

ID=22326932

Family Applications (1)

Application Number Title Priority Date Filing Date
UA96020584A UA63876C2 (en) 1993-08-19 1994-08-15 Method for treating schizophrenia and schizophreniform disorders

Country Status (23)

Country Link
EP (1) EP0734259B1 (de)
JP (1) JP3126736B2 (de)
KR (1) KR100360575B1 (de)
CN (1) CN1087936C (de)
AT (1) ATE218864T1 (de)
AU (1) AU701292B2 (de)
CA (1) CA2169839C (de)
CZ (1) CZ285030B6 (de)
DE (1) DE69430816T2 (de)
DK (1) DK0734259T3 (de)
ES (1) ES2177581T3 (de)
FI (2) FI960747A7 (de)
HU (1) HU221729B1 (de)
IL (1) IL110708A (de)
NO (1) NO312706B1 (de)
NZ (2) NZ336597A (de)
PT (1) PT734259E (de)
RU (1) RU2191580C2 (de)
SG (1) SG55071A1 (de)
TW (1) TW442284B (de)
UA (1) UA63876C2 (de)
WO (1) WO1995005174A1 (de)
ZA (1) ZA946324B (de)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5821371A (en) * 1994-10-24 1998-10-13 Eli Lilly And Comany Heterocyclic compounds and their preparation and use
US5998404A (en) * 1994-10-24 1999-12-07 Eli Lilly And Company Heterocyclic compounds and their use
US5605908A (en) * 1994-10-24 1997-02-25 Eli Lilly And Company Heterocyclic compounds and their use
US5574028A (en) * 1994-10-31 1996-11-12 Eli Lilly And Company Method for treating anxiety
CA2202776A1 (en) * 1994-10-31 1996-05-09 Franklin Porter Bymaster Method for treating anxiety
US5488056A (en) * 1994-10-31 1996-01-30 Eli Lilly And Company Method for treating anxiety
US5726193A (en) * 1994-10-31 1998-03-10 Eli Lilly And Company Method for treating anxiety
US5565475A (en) * 1994-11-08 1996-10-15 Muhlhauser; Mark A. Method of treating urinary bladder dysfunctions with 3-tetrahydropyridine derivatives
US5763457A (en) * 1995-11-13 1998-06-09 Eli Lilly And Company Method for treating anxiety
US5852037A (en) * 1995-11-13 1998-12-22 Eli Lilly And Company Method for treating anxiety
US6043258A (en) * 1996-08-01 2000-03-28 Eli Lilly And Company Method for treating disruptive behavior disorders with xanomeline
EP0821959A3 (de) * 1996-08-01 1998-09-16 Eli Lilly And Company Verwendung von 3-(4-Hexyloxy-1,2,5-Thiadiazol-3-yl)-1,2,5,6-Tetrahydro-1-Methylpyridin zur Behandlung von Nikotin-Entzug
EP0821955B1 (de) * 1996-08-01 2002-02-20 Eli Lilly And Company Verwendung von 3-(4-Hexyloxy-1,2,5-Thiadiazol-3-yl)-1,2,5,6-Tetrahydro-1-Methylpyridin (Xanomelin) zur Behandlung von bipolaren Störungen
US6090829A (en) * 1996-08-01 2000-07-18 Eli Lilly And Company Method for treating excessive aggression
EP0821954A1 (de) * 1996-08-01 1998-02-04 Eli Lilly And Company Verfahren zur Behandlung von geistiger Zurückgebliebenheit
US6117890A (en) * 1996-08-01 2000-09-12 Eli Lilly And Company Method for treating bipolar disorder
EP0821957A3 (de) * 1996-08-01 1998-04-22 Eli Lilly And Company Verwendung von 3-(4-Hexyloxy-1,2,5-Thiadiazol-3-yl)-1,2,5,6-Tetrahydro-1-Methylpyridin (Xanomelin) zur Behandlung von Drogenmissbrauch
EP0821958A3 (de) * 1996-08-01 1998-07-08 Eli Lilly And Company Verwendung von 3-(4-Hexyloxy-1,2,5-Thiadiazol-3-yl)-1,2,5,6-Tetrahydro-1-Methylpyridin (Xanomelin) zur Behandlung von übermässiger Streitsucht
EP0821956A1 (de) * 1996-08-01 1998-02-04 Eli Lilly And Company Verfahren zur Behandlung disruptiver Verhaltensstörungen
DE69825605T2 (de) 1997-05-29 2005-09-15 H. Lundbeck A/S Behandlung der schizophrenie und der psychose
US6034108A (en) * 1997-07-28 2000-03-07 Eli Lilly And Company Method for treating mental retardation
ES2742728T3 (es) 2009-07-22 2020-02-17 PureTech Health LLC Composiciones para el tratamiento de trastornos mejorados por la activación del receptor muscarínico
PT3856182T (pt) * 2018-09-28 2026-03-10 Karuna Therapeutics Inc Composições e métodos para o tratamento de perturbações melhoradas pela ativação dos recetores muscarínicos
WO2021097427A1 (en) 2019-11-15 2021-05-20 Karuna Therapeutics, Inc. Xanomeline derivatives and methods for treating neurological disorders
WO2023061372A1 (zh) * 2021-10-14 2023-04-20 南京迈诺威医药科技有限公司 占诺美林衍生物的苹果酸盐、a晶型及其制备方法和用途
CN119161338B (zh) * 2024-11-25 2025-06-17 嘉兴安帝康生物科技有限公司 用作毒蕈碱受体激动剂的四氢吡啶衍生物及其在医药上的应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ225999A (en) * 1987-09-10 1992-04-28 Merck Sharp & Dohme Azacyclic- or azabicyclic-substituted thiadiazole derivatives and pharmaceutical compositions
US5043345A (en) * 1989-02-22 1991-08-27 Novo Nordisk A/S Piperidine compounds and their preparation and use
DK198490D0 (da) * 1990-08-21 1990-08-21 Novo Nordisk As Heterocykliske forbindelser, deres fremstilling og anvendelse
DK198390D0 (da) * 1990-08-21 1990-08-21 Novo Nordisk As Heterocykliske forbindelser, deres fremstilling og anvendelse

Also Published As

Publication number Publication date
KR960703592A (ko) 1996-08-31
CZ42696A3 (en) 1996-11-13
NZ336597A (en) 2001-02-23
SG55071A1 (en) 1998-12-21
IL110708A0 (en) 1994-11-11
NZ271311A (en) 1999-09-29
JPH09501658A (ja) 1997-02-18
ES2177581T3 (es) 2002-12-16
ZA946324B (en) 1996-02-19
ATE218864T1 (de) 2002-06-15
NO312706B1 (no) 2002-06-24
AU701292B2 (en) 1999-01-21
CA2169839C (en) 2002-06-11
JP3126736B2 (ja) 2001-01-22
RU2191580C2 (ru) 2002-10-27
KR100360575B1 (ko) 2003-03-10
NO960619D0 (no) 1996-02-16
WO1995005174A1 (en) 1995-02-23
FI960747L (fi) 1996-04-17
HU221729B1 (hu) 2002-12-28
FI20050461L (fi) 2005-04-29
FI20050461A7 (fi) 2005-04-29
DE69430816T2 (de) 2002-12-19
CA2169839A1 (en) 1995-02-23
AU7490294A (en) 1995-03-14
EP0734259A1 (de) 1996-10-02
EP0734259B1 (de) 2002-06-12
TW442284B (en) 2001-06-23
DK0734259T3 (da) 2002-09-30
PT734259E (pt) 2002-11-29
IL110708A (en) 1998-12-06
FI960747A7 (fi) 1996-04-17
HU9600364D0 (en) 1996-04-29
NO960619L (no) 1996-04-18
FI960747A0 (fi) 1996-02-19
CN1133008A (zh) 1996-10-09
CN1087936C (zh) 2002-07-24
DE69430816D1 (de) 2002-07-18
HUT75111A (en) 1997-04-28
CZ285030B6 (cs) 1999-05-12

Similar Documents

Publication Publication Date Title
DE69430816T2 (de) Verwendung von Piperidin-Derivaten in der Behandlung von Schizophrenie
US5773452A (en) Heterocyclic compounds and their use
KR0163763B1 (ko) 피페리딘 화합물, 이의 제조방법 및 용도
CA2202775C (en) Method for treating anxiety
JP3100159B2 (ja) 複素環式化合物及びそれらの調製及び用途
CA2202776A1 (en) Method for treating anxiety
US5744489A (en) Method of treating gastrointestinal motility disorders
RU2314305C2 (ru) Производные 4-(тио- или селеноксантен-9-илиден)-пиперидина или акридина, фармацевтическая композиция на их основе и применение
US5750541A (en) Method of treating schizophrenia
US5565475A (en) Method of treating urinary bladder dysfunctions with 3-tetrahydropyridine derivatives
US5545638A (en) Method of treating gastrointestinal motility disorders